Neurogene Opens Natural History Study of CLN7, CLN5 Diseases at UT Southwestern
The goal of the study is to better understand the course of Batten disease and to determine clinically meaningful outcome measures for use in future gene therapy trials.
Aug 9, 2019 | By Ana Pena | Batten Disease News
Neurogene is sponsoring a natural history study to better understand the course of CLN5 and CLN7 disease, two forms of late-infantile Batten disease, and to find meaningful ways of measuring patient outcomes for use in gene therapy trials.
The study is running as part of a collaboration between Neurogene and UT Southwestern Medical Center (UTSW).
“CLN7 and CLN5 are devastating and severe neurological diseases, and there are currently no treatments for them,” Berge Minassian, MD, division chief of child neurology at UT Southwestern Medical Center, said in a press release.
“Through this study, and thanks to those in the Batten disease community who choose to participate, we will soon know much more about how the disease affects those who suffer from it so that we may help the many children in need.”
Batten disease, also called neuronal ceroid lipofuscinoses (NCL), is a group of rare inherited neurological conditions caused by mutations that disturb a cell’s ability to get rid of waste products. This leads to a buildup of toxic deposits composed of fats and proteins, called lipofuscins, in tissues across the body, especially in nerve cells in the brain and cells of the eye, as well as in the skin and other tissues.
CLN5 and CLN7 are rare, pediatric-onset and rapidly progressive forms of the disease, caused by defects in the CLN5 and CLN7/MFSD8 genes, respectively.
These types of late infantile Batten disease are marked by seizures, progressive deterioration of motor skills and cognitive ability, loss of vision, and premature death.
The purpose of Neurogene’s natural history study (NCT03822650) is to investigate the clinical characteristics and natural progression of symptoms. It’s an observational study, which means no interventions will be made nor will any investigational therapy be given to participants.
The study expects to enroll 30 patients with genetically confirmed CLN5 or CLN7 disease, a mix of children and adults. Participants will undergo multiple assessments over time to address disease course, including electroencephalography or EEG, neuropsychological and ophthalmological evaluations, and brain MRI scans.
Its principal investigator is Saima Kayani, MD, a professor of pediatric neurology at UTSW. Enrollment is ongoing at UT Southwestern Medical Center in Dallas, and additional information is available here.
“Neurogene is committed to reimagining the future for people living with rare neurological diseases,” said Effie Albanis, MD, Neurogene’s chief medical officer. “This natural history study of CLN7 and CLN5 will be instrumental in designing a gene therapy to treat these rare forms of Batten disease.”
TRNDS 2019
University of Rochester
Saunders Research Building
Helen Wood Hall Auditorium
255 Crittenden Blvd
Rochester, NY 14642
Date: Friday, September 13
Time: 7:30 am – 4:00pm
TRNDS News
Sign-up for TRNDS updates and rare disease news
-
New Grants will Accelerate Clinical Trials in Rare Neurological Disorders
-
Neurogene Offers Access to Genetic Testing for Lysosomal Storage Disease
-
NIH launches 5-year, $10 million study on acute flaccid myelitis
-
Study refines ALS risk among first-degree relatives of patients with disease
-
NCATS Director Warns of 'Poorly Understood Public Health Implications of Rare Diseases'
-
Speeding Up Drug Discovery for Brain Diseases
-
NIH-Funded Project Aims to Build a ‘Google’ for Biomedical Data
-
Rare Disease Groups Seek Public Support to Renew Newborn Screening Act in Senate
-
(Podcast) Get to know Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics
-
Meet TRNDS 2019 Speaker PJ Brooks
-
Rare Pediatric Disease PRVs: FDA Updates Guidance
-
Neurogene Opens Natural History Study of CLN7, CLN5 Diseases at UT Southwestern
-
C-Path and NORD Collaborate to Launch Rare Disease Data Platform
-
Meet TRNDS Speaker Tauna Batiste
-
HD Patients Prefer Less Invasive, No-Placebo Gene Therapy Trials
-
Evidation & Eli Lilly Study Uses Apple Devices, Apps to Predict Cognitive Impairment
-
'Dr. Google' Helps Some Patients Diagnose a Rare Disease
-
Antisense Drugs for HD, ALS & Prion Could Meet the Need for Brain Treatments
-
Ultragenyx Partners with GeneTx to Advance Treatment for Angelman Syndrome
-
Netflix's Medical Investigation Docuseries 'Diagnosis'
-
NIH All of Us Project Tops 270,000 Sign-ups
-
FDA Cancer Office Taps Syapse for Real-world Evidence Development
-
Gene Linked to Rare Neurological Disorder May Play a Role in Alzheimer’s
-
Gene Therapy Developers Issue Principles for Human Genome Editing
-
Forget Single Genes: CRISPR Now Cuts & Splices Whole Chromosomes
-
TRNDS Speaker Benjamin Schlatka, MC10
-
TRNDS Speaker Danielle Edwards, Jett Foundation
-
His daughter has a rare disorder. He’s developing a novel gene therapy.
-
A Doctor Tested a New Treatment on Himself, Now it's Saving Other Lives
-
Study Presents Clinical, Genetic Landscape of Pompe Disease
Room Block
Hilton Garden Inn
Rochester/University
Medical Center
30 Celebration Drive
Rochester, NY 14620
Phone: 585-424-4404
TRNDS Rate: $149/night